Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Milan Lukas

Showing results (21-30 of 77) with videos related to

Pageof 8
Sort By:
Inflammatory Bowel Diseases|November 4, 2009
Exogenous alkaline phosphatase for the treatment of patients with moderate to severe ulcerative colitisMilan Lukas, Pavel Drastich, Michal Konecny, et al.
Scandinavian Journal of Gastroenterology|July 10, 2013
Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-α therapy during pregnancy: three-center studyMartin Bortlik, Nadezda Machkova, Dana Duricova, et al.
Inflammatory Bowel Diseases|December 9, 2016
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist TherapyBruce E Sands, William J Sandborn, Gert Van Assche, et al.
European Journal of Pediatrics|July 18, 2024
Serological responses to vaccination in children exposed in utero to ustekinumab or vedolizumab: cross-sectional analysis of a prospective multicentre cohortKatarina Mitrova, Karin Cerna, Kristyna Zdychyncova, et al.
Journal of Pediatric Gastroenterology and Nutrition|July 11, 2009
Association of IL23R p.381Gln and ATG16L1 p.197Ala with Crohn disease in the Czech populationPetra Dusatkova, Ondrej Hradsky, Martin Lenicek, et al.
Dermatologic Therapy|June 7, 2014
Visceral leishmaniasis with cutaneous symptoms in a patient treated with infliximab followed by fatal consequencesKaterina Juzlova, Jana Votrubova, Denisa Kacerovska, et al.
Gastroenterology|February 14, 2006
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trialStephen B Hanauer, William J Sandborn, Paul Rutgeerts, et al.
Gastrointestinal Endoscopy|March 5, 2025
Risk factors for difficult endoscopic bowel dilation of predominantly shorter and noninflammatory strictures among patients with inflammatory bowel disease: findings from inflammatory bowel disease tertiary centers in Poland and Czech RepublicKonrad Lewandowski, Martin Lukas, Magdalena Kaniewska, et al.
Gastrointestinal Endoscopy|July 16, 2025
ResponseKonrad Lewandowski, Martin Lukas, Magdalena Kaniewska, et al.
Scandinavian Journal of Gastroenterology|September 3, 2015
Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observationMartin Bortlik, Dana Duricova, Nadezda Machkova, et al.
Pageof 8

Showing results (21-30 of 77) with videos related to

Sort By:
Pageof 8
Inflammatory Bowel Diseases|November 4, 2009
Exogenous alkaline phosphatase for the treatment of patients with moderate to severe ulcerative colitisMilan Lukas, Pavel Drastich, Michal Konecny, et al.
Scandinavian Journal of Gastroenterology|July 10, 2013
Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-α therapy during pregnancy: three-center studyMartin Bortlik, Nadezda Machkova, Dana Duricova, et al.
Inflammatory Bowel Diseases|December 9, 2016
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist TherapyBruce E Sands, William J Sandborn, Gert Van Assche, et al.
European Journal of Pediatrics|July 18, 2024
Serological responses to vaccination in children exposed in utero to ustekinumab or vedolizumab: cross-sectional analysis of a prospective multicentre cohortKatarina Mitrova, Karin Cerna, Kristyna Zdychyncova, et al.
Journal of Pediatric Gastroenterology and Nutrition|July 11, 2009
Association of IL23R p.381Gln and ATG16L1 p.197Ala with Crohn disease in the Czech populationPetra Dusatkova, Ondrej Hradsky, Martin Lenicek, et al.
Dermatologic Therapy|June 7, 2014
Visceral leishmaniasis with cutaneous symptoms in a patient treated with infliximab followed by fatal consequencesKaterina Juzlova, Jana Votrubova, Denisa Kacerovska, et al.
Gastroenterology|February 14, 2006
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trialStephen B Hanauer, William J Sandborn, Paul Rutgeerts, et al.
Gastrointestinal Endoscopy|March 5, 2025
Risk factors for difficult endoscopic bowel dilation of predominantly shorter and noninflammatory strictures among patients with inflammatory bowel disease: findings from inflammatory bowel disease tertiary centers in Poland and Czech RepublicKonrad Lewandowski, Martin Lukas, Magdalena Kaniewska, et al.
Gastrointestinal Endoscopy|July 16, 2025
ResponseKonrad Lewandowski, Martin Lukas, Magdalena Kaniewska, et al.
Scandinavian Journal of Gastroenterology|September 3, 2015
Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observationMartin Bortlik, Dana Duricova, Nadezda Machkova, et al.
Pageof 8